The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.
 
Syed A. Hussain
Honoraria - Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Merck; Pfizer; Roche
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Janssen; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme